Policy specialists PsychedelicsEUROPE and biopharma company, Mycotopia Therapies, are partnering to explore opportunities for psychedelic care on the continent.
As research into psychedelics continues to grow, a new peer reviewed scientific journal – Psychedelic Medicine – will be launched in 2023 to provide a high-profile...
Numinus Wellness is hosting a series of immersive events – Music as Medicine – to highlight the role that music can play in healing.
Pharmadrug has announced it is advancing its opthalmology programme with the selection of its lead DMT analogue as a potential treatment for primary open angle glaucoma...
Nirvana Life Sciences has announced it is making progress with its Health Canada Dealer’s licence application and its facility development.
CYB004 – which is being developed for anxiety disorders – has shown that it has a similar onset of effect and dose profile to IV DMT...
A Phase II trial is being conducted to investigate the potential of psilocybin-assisted psychotherapy as a treatment for binge eating disorder (BED).
In vivo findings have demonstrated that the amanita muscaria extract – AME-1 – indicate a potential priming effect on the immune system, allowing it to more...
Albert Labs has appointed Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira to its scientific advisory board (SAB).
With growing scientific interest in the area of psychedelics, Duke University has launched the Center for Integrated Psychedelic Science (CIPS).
Cybin has partnered with Clinilabs to carry out its Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analogue.
Mental wellness company Nue Life Health has announced the completion of its Series A equity financing led by Obvious Ventures.
